GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.

BACKGROUND Tumor intraductal carcinoma/cribriform architecture (IDC/C) is associated with an unfavorable prognosis and biochemical recurrence (BCR) in prostate cancer (PCa). Up to 70% of PCa patients are IDC/C-negative, but it is estimated that 20% of these cases still experience BCR. Thus, biomarkers for better detection of aggressive disease in IDC/C-negative patients are required. OBJECTIVE To investigate tumor-specific methylation of the transcription factor GBX2 as a novel prognosticator and predictor of BCR in PCa patients stratified by histopathologic features including IDC/C. DESIGN, SETTING, AND PARTICIPANTS Using genome-wide methylome profiling, we identified higher GBX2 methylation in grade group (GG) 4 tumors compared to GG1 (discovery cohort). The prognostic nature of GBX2 methylation was validated in silico using The Cancer Genome Atlas data (n=478) and a quantitative methylation assay for radical prostatectomy samples (n=254). Regulation of GBX2 methylation was investigated in prostate cells using methyl-CpG-binding domain sequencing and methylation analysis in functional knockouts of TET2, a key epigenetic player in prostate carcinogenesis. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS The association of GBX2 methylation with Gleason score (GS), pathologic stage (pT), IDC/C, and BCR was analyzed using Kruskal-Wallis and Mann-Whitney tests. Univariate and multivariate Cox regression analyses were used to predict BCR. RESULTS GBX2 methylation was associated with GS (p<0.05), pT (p<0.01), and BCR (p<0.05). GBX2 methylation (p=0.004), GS (p<0.001), pT (p=0.012), and prostate-specific antigen (p=0.005) were independent predictors of BCR. Among IDC/C-negative patients, GBX2 methylation improved prediction of BCR (p=0.002). Loss of TET2 in prostate cells resulted in greater GBX2 methylation. CONCLUSIONS We identified GBX2 methylation as a novel prognostic factor in PCa and an independent predictor of BCR. We demonstrated the additive value of GBX2 methylation in predicting BCR among IDC/C-negative patients and elucidated a novel TET2-mediated upstream epigenetic regulatory mechanism of GBX2. PATIENT SUMMARY We identified GBX2 methylation as a promising prognostic biomarker that could improve the identification of prostate cancer patients at higher risk of biochemical recurrence.

[1]  Takafumi N. Yamaguchi,et al.  Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations , 2018, BMC Cancer.

[2]  T. H. van der Kwast,et al.  A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. , 2017, European urology.

[3]  T. H. van der Kwast,et al.  Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression , 2011, International journal of cancer.

[4]  L. Egevad,et al.  A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. , 2016, European urology.

[5]  Mark S. Litwin,et al.  The Diagnosis and Treatment of Prostate Cancer: A Review , 2017, JAMA.

[6]  T. H. van der Kwast,et al.  Discovery of Novel Hypermethylated Genes in Prostate Cancer Using Genomic CpG Island Microarrays , 2009, PloS one.

[7]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[8]  Faraz Hach,et al.  Spatial genomic heterogeneity within localized, multifocal prostate cancer , 2015, Nature Genetics.

[9]  Peng Qiu,et al.  TCGA-Assembler: open-source software for retrieving and processing TCGA data , 2014, Nature Methods.

[10]  Esther I Verhoef,et al.  Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy , 2016, Modern Pathology.

[11]  T. H. van der Kwast,et al.  Novel Multiplex MethyLight Protocol for Detection of DNA Methylation in Patient Tissues and Bodily Fluids , 2014, Scientific Reports.

[12]  Y. Homma,et al.  Correction: Corrigendum: TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression , 2015, Nature Communications.

[13]  Jing Ma,et al.  Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Mahul B Amin,et al.  Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2017, The American journal of surgical pathology.

[15]  J. Isaacs,et al.  Enhanced GBX2 expression stimulates growth of human prostate cancer cells via transcriptional up-regulation of the interleukin 6 gene. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  T. H. van der Kwast,et al.  Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors. , 2017, Oncology letters.

[17]  J. Isaacs,et al.  Down-regulation of homeobox gene GBX2 expression inhibits human prostate cancer clonogenic ability and tumorigenicity. , 1998, Cancer research.

[18]  Jonathan Epstein,et al.  Grading of prostatic adenocarcinoma: current state and prognostic implications , 2016, Diagnostic Pathology.

[19]  J. Trachtenberg,et al.  DNA methylation of HOXD3 as a marker of prostate cancer progression , 2010, Laboratory Investigation.

[20]  A W Partin,et al.  Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. , 2000, Urology.

[21]  I. Thompson,et al.  Roles of Distal and Genic Methylation in the Development of Prostate Tumorigenesis Revealed by Genome-wide DNA Methylation Analysis , 2016, Scientific Reports.

[22]  Gary D Bader,et al.  Dynamic interplay between locus-specific DNA methylation and hydroxymethylation regulates distinct biological pathways in prostate carcinogenesis , 2016, Clinical Epigenetics.

[23]  Y. Homma,et al.  TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression , 2015, Nature Communications.

[24]  A. Bird,et al.  CpG islands and the regulation of transcription. , 2011, Genes & development.

[25]  T. H. van der Kwast,et al.  Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. , 2014, European journal of cancer.